← Back to Screener
Catalyst Pharmaceutical Inc. (CPRX)
Price$31.27
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)21.22%
Price vs S&P 500 (4W)3.69%
VGM Score62.25
Market Capitalization$3.82B
P/E Ratio (Annual)17.83x
All Metrics
P/CF (Annual)18.32x
Book Value / Share (Quarterly)$8.29
P/TBV (Annual)3.49x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)40.10%
Cash Flow / Share (Quarterly)$1.70
Price vs S&P 500 (YTD)22.87%
Gross Margin (TTM)85.96%
Net Profit Margin (TTM)37.08%
EPS (TTM)$1.74
10-Day Avg Trading Volume2.60M
EPS Excl Extra (TTM)$1.74
Revenue Growth (5Y)37.67%
EPS (Annual)$1.68
ROI (Annual)22.46%
Gross Margin (Annual)85.19%
Net Profit Margin (5Y Avg)30.90%
Cash / Share (Quarterly)$6.19
P/E Basic Excl Extra (TTM)17.27x
Revenue Growth QoQ (YoY)5.63%
EPS Growth (5Y)18.99%
P/E Normalized (Annual)17.83x
ROA (Last FY)19.41%
Revenue Growth TTM (YoY)11.65%
EBITD / Share (TTM)$2.40
ROE (5Y Avg)22.03%
Operating Margin (TTM)44.83%
Cash Flow / Share (Annual)$1.70
P/B Ratio3.77x
P/B Ratio (Quarterly)2.99x
Net Income / Employee (Annual)$1,177,600
EV / Revenue (TTM)5.14x
Net Interest Coverage (TTM)-91.00x
ROA (TTM)20.71%
EPS Growth QoQ (YoY)12.37%
EV / EBITDA (TTM)10.04x
EPS Incl Extra (Annual)$1.68
Current Ratio (Annual)6.08x
Quick Ratio (Quarterly)6.72x
3-Month Avg Trading Volume1.82M
52-Week Price Return27.05%
EV / Free Cash Flow (Annual)14.70x
P/E Incl Extra (TTM)17.27x
Revenue / Employee (TTM)$3,280,000
Tangible BV / Share (Quarterly)$7.29
P/S Ratio (Annual)6.49x
Asset Turnover (Annual)0.53x
52-Week High$32.56
Operating Margin (5Y Avg)38.00%
EPS Excl Extra (Annual)$1.68
Tangible BV CAGR (5Y)27.04%
26-Week Price Return37.15%
Quick Ratio (Annual)5.70x
13-Week Price Return25.52%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.10x
Enterprise Value$3.07B
Revenue / Share Growth (5Y)32.78%
Asset Turnover (TTM)0.56x
Book Value / Share Growth (5Y)36.66%
Revenue / Employee (Annual)$3,236,200
Inventory Turnover (Annual)3.08x
Pretax Margin (Annual)48.14%
Cash / Share (Annual)$5.79
3-Month Return Std Dev37.57%
Gross Margin (5Y Avg)85.31%
Net Income / Employee (TTM)$1,216,100
EBITDA CAGR (5Y)48.13%
EBITDA Interim CAGR (5Y)52.98%
ROE (Last FY)22.46%
Net Interest Coverage (Annual)-17.00x
EPS Basic Excl Extra (Annual)$1.68
P/FCF (TTM)18.36x
Receivables Turnover (TTM)5.91x
EV / Free Cash Flow (TTM)14.73x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.74
Receivables Turnover (Annual)6.14x
ROI (TTM)23.65%
P/S Ratio (TTM)6.40x
Pretax Margin (5Y Avg)40.43%
Revenue / Share (Annual)$4.63
Tangible BV / Share (Annual)$6.71
Forward P/E15.25x
Free OCF CAGR (5Y)35.90%
Price vs S&P 500 (52W)-1.15%
P/E Ratio (TTM)17.27x
EPS Growth TTM (YoY)10.72%
Year-to-Date Return33.80%
5-Day Price Return-0.10%
EPS Normalized (Annual)$1.68
ROA (5Y Avg)18.52%
Net Profit Margin (Annual)36.39%
Month-to-Date Return11.02%
Cash Flow / Share (TTM)$0.77
EBITD / Share (Annual)$2.32
EPS Growth (3Y)31.19%
Operating Margin (Annual)43.77%
P/CF (TTM)18.36x
ROI (5Y Avg)22.03%
P/E Excl Extra (TTM)17.27x
EPS Basic Excl Extra (TTM)$1.74
P/TBV (Quarterly)3.39x
P/B Ratio (Annual)3.01x
Inventory Turnover (TTM)3.06x
Pretax Margin (TTM)49.66%
Book Value / Share (Annual)$7.79
Price vs S&P 500 (13W)15.78%
Net Margin Growth (5Y)-10.39%
Beta0.75x
P/FCF (Annual)18.32x
Revenue / Share (TTM)$4.70
ROE (TTM)23.65%
52-Week Low$19.05
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.50est. 0.47
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.43
4.43
4.43
4.43
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CPRXCatalyst Pharmaceutical Inc. | C | B | B | $31.27 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company commercializes three FDA-approved drugs: FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). It pursues growth through acquiring accretive assets, including clinical-stage candidates with established proof of concept.